Form 4: Athira Pharma Director Michael Panzara Granted Stock Options as Part of Compensation Policy

Athira Pharma, Inc. Director Michael A. Panzara was granted 20,900 stock options with an exercise price of $0.3125, aligning his interests with shareholder value.

Summary

• Michael A. Panzara, a Director of Athira Pharma, Inc. (ATHA), acquired 20,900 stock options on May 30, 2025.
• The stock options have an exercise price of $0.3125 per share.
• These options were granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
• The shares subject to the option will vest on the earlier of May 30, 2026, or the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025.
• The options expire on May 29, 2035.
• Following this transaction, Mr. Panzara beneficially owns 20,900 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects a standard practice of aligning director interests with shareholders through equity compensation. It's not highly impactful on its own but contributes to good governance.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the value of the options increases with the company's stock price.
• The transaction is part of a pre-defined Outside Director Compensation Policy, indicating a structured approach to executive remuneration.

Future Outlook

The future outlook related to this specific filing pertains to the vesting of the granted stock options, which will occur on the earlier of May 30, 2026, or the day before the next annual meeting of stockholders after May 30, 2025. The options have a long-term expiration date of May 29, 2035, providing a significant window for potential exercise.

Management Comments

• The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

Industry Context

The grant of stock options to outside directors is a common practice in the biotechnology and pharmaceutical industry, as well as across many other sectors, to attract and retain qualified board members and align their long-term interests with company performance and shareholder value. This is a standard form of equity compensation.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a widely accepted practice across industries, including biotech, aligning director incentives with long-term company performance.
• The vesting schedule, tied to a specific date or the next annual meeting, is a typical structure for director equity awards, ensuring continued engagement and oversight.
• The exercise price being set at a specific value (e.g., market price at grant or a nominal value for certain types of awards) is standard, though the specific value of $0.3125 would need to be compared to the stock's market price on the grant date to assess its immediate 'in-the-money' or 'out-of-the-money' status, which is not provided in this Form 4.

Corporate Governance

Related Party Transactions

• The grant of stock options to Michael A. Panzara, a director of Athira Pharma, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's financial interests with long-term shareholder value creation, as the options become more valuable if the stock price increases.
• Employees: No direct impact on general employees is indicated by this specific filing, though it reflects the company's overall compensation philosophy for its leadership.

Next Steps

• The granted stock options will vest on the earlier of May 30, 2026, or the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025.
• Upon vesting, Michael A. Panzara will have the right to exercise these options to acquire common stock of Athira Pharma, Inc. at the specified exercise price until the expiration date of May 29, 2035.

Key Dates

Keywords

Athira Pharma, ATHA, Form 4, Stock Option, Director Compensation, Insider Transaction, Michael A. Panzara, Equity Compensation